Immunome (IMNM) versus Its Peers Head to Head Review

Immunome (NASDAQ:IMNM) is one of 843 public companies in the “Biotechnology” industry, but how does it compare to its peers? We will compare Immunome to related companies based on the strength of its analyst recommendations, valuation, risk, institutional ownership, profitability, earnings and dividends.

Valuation and Earnings

This table compares Immunome and its peers top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Immunome	$6.94 million	-$212.39 million	-7.11
Immunome Competitors	$718.54 million	$11.20 million	-18.80

Immunome’s peers have higher revenue and earnings than Immunome. Immunome is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares Immunome and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Immunome	N/A	-51.33%	-47.63%
Immunome Competitors	-12,319.70%	-407.93%	-30.95%

Insider & Institutional Ownership

44.6% of Immunome shares are owned by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are owned by institutional investors. 7.2% of Immunome shares are owned by company insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings for Immunome and its peers, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunome	1	1	14	0	2.81
Immunome Competitors	9903	15310	45655	1602	2.54

Immunome currently has a consensus price target of $33.85, suggesting a potential upside of 80.32%. As a group, “Biotechnology” companies have a potential upside of 126.31%. Given Immunome’s peers higher possible upside, analysts clearly believe Immunome has less favorable growth aspects than its peers.

Volatility and Risk

Immunome has a beta of 2.68, suggesting that its stock price is 168% more volatile than the S&P 500. Comparatively, Immunome’s peers have a beta of -1.88, suggesting that their average stock price is 288% less volatile than the S&P 500.

Summary

Immunome peers beat Immunome on 7 of the 13 factors compared.

Immunome Company Profile

Immunome is a biotechnology company focused on discovering and developing therapies for cancer. It uses an antibody-discovery platform to identify targets and develop medicines intended to address areas of significant unmet medical need. The company’s research and development programs include targeted cancer treatments, such as antibody-based therapies and other drug candidates. Its portfolio has included investigational medicines for solid tumors and other cancers; these products are in development and are not necessarily approved for commercial use.